Blog | HemaCare

Point-of-Care Device May Improve Outcomes for Patients with Critical Limb Ischemia

Dec 21, 2016 12:00:16 AM / by Stacy Matthews Branch, DVM, PhD

Researchers test a new treatment approach for Critical Limb involving CD34 stem cells from bone marrow aspirate supplied by HemaCare.Researchers use bone marrow provided by HemaCare to help patients with critical limb ischemia.

Critical limb ischemia (CLI) is a condition caused by blocked arteries leading to low blood flow to the legs, feet, and other extremities. This causes severe pain, skin sores, gangrene, and can also lead to death. Amputation is often needed due to a lack of effective treatment options for CLI. The poor outcomes for patients with CLI have stimulated research efforts to find effective treatments such as autologous cell therapies. A new approach to treatment that is being investigated involves using cells from bone marrow aspirate supplied by HemaCare (bone marrow collected with a needle and syringe).

The benefits of using bone marrow aspirate are the presence of stromal stem cells and hematopoietic cells such as CD34 stem cells. This is important because stem cells may play crucial roles in tissue regeneration. However, one drawback is the small number of stem cells present in bone marrow aspirate. There have been clinical trials using concentration devices (employing the Ficoll gradient centrifugation method) to isolate the bone marrow cells, but these devices require many steps and manipulations that make the approach nearly impractical for clinical use.

A more recent clinical study investigated the cell output for another device, a point-of-care cell separator, to determine its clinical utility to treat CLI. The use of this device (MarrowStim P.A.D. Kit) to isolate cells in the patient care setting relieves many of the limitations of the standard Ficoll method. Various bone marrow cell types were collected in the study including CD34 stem cells and other progenitor cells. The MarrowStim P.A.D. Kit was able to output considerably more stem cells than the Ficoll method.

These results give promise for the replacement of a laborious cell concentration method by a more efficient point-of-care method to isolate stem cells. The information provided about the studied device’s cellular output can be used to better determine how effective it is in treating CLI in clinical trials. Also, if the new method is safe and effective, it can be used early in the disease process to increase survival and improve outcomes for patients with CLI.

At HemaCare, we pride ourselves in providing researchers the best-possible bioresearch products they need to better the future. Order your cells online today online or call 877-397-3087.

Reference:
Woodell-May, Jennifer E. et al. "Characterization Of The Cellular Output Of A Point-Of-Care Device And The Implications For Addressing Critical Limb Ischemia". N.p., 2016. Print.

Topics: Bone Marrow, cd 34 stem cells, Critical Limb Ischemia, Point of care device, research, stem cell research

Subscribe Here!

Posts by Topic

see all

Recent Posts